Brokerage Firm Rating on AEterna Zentaris (AEZS)

AEterna Zentaris (AEZS) : Zacks Investment Research ranks AEterna Zentaris (AEZS) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 4 research analysts is 1.25, which indicates as a Strong Buy.

AEterna Zentaris (AEZS) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $12 and the lowest price target forecast is $10. The average forecast of all the analysts is $11 and the expected standard deviation is $0.82.


For the current week, the company shares have a recommendation consensus of Buy. AEterna Zentaris (NASDAQ:AEZS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.48 and $3.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.55. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.54, notching a gain of 2.61% for the day. The total traded volume was 99,169 . The stock had closed at $3.45 on the previous day.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.